3
|
Zheng J, Hong BV, Agus JK, Tang X, Klebaner NR, Chen S, Guo F, Harvey DJ, Lebrilla CB, Zivkovic AM. Lutein and Zeaxanthin Enhance, Whereas Oxidation, Fructosylation, and Low pH Damage High-Density Lipoprotein Biological Functionality. Antioxidants (Basel) 2024; 13:616. [PMID: 38790721 PMCID: PMC11118252 DOI: 10.3390/antiox13050616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Revised: 05/14/2024] [Accepted: 05/15/2024] [Indexed: 05/26/2024] Open
Abstract
High-density lipoproteins (HDLs) are key regulators of cellular cholesterol homeostasis but are functionally altered in many chronic diseases. The factors that cause HDL functional loss in chronic disease are not fully understood. It is also unknown what roles antioxidant carotenoids play in protecting HDL against functional loss. The aim of this study was to measure how various disease-associated chemical factors including exposure to (1) Cu2+ ions, (2) hypochlorous acid (HOCL), (3) hydrogen peroxide (H2O2), (4) sialidase, (5) glycosidase, (6) high glucose, (7) high fructose, and (8) acidic pH, and the carotenoid antioxidants (9) lutein and (10) zeaxanthin affect HDL functionality. We hypothesized that some of the modifications would have stronger impacts on HDL particle structure and function than others and that lutein and zeaxanthin would improve HDL function. HDL samples were isolated from generally healthy human plasma and incubated with the corresponding treatments listed above. Cholesterol efflux capacity (CEC), lecithin-cholesterol acyl transferase (LCAT) activity, and paraoxonase-1 (PON1) activity were measured in order to determine changes in HDL functionality. Median HDL particle diameter was increased by acidic pH treatment and reduced by HOCl, high glucose, high fructose, N-glycosidase, and lutein treatments. Acidic pH, oxidation, and fructosylation all reduced HDL CEC, whereas lutein, zeaxanthin, and sialidase treatment improved HDL CEC. LCAT activity was reduced by acidic pH, oxidation, high fructose treatments, and lutein. PON1 activity was reduced by sialidase, glycosidase, H2O2, and fructose and improved by zeaxanthin and lutein treatment. These results show that exposure to oxidizing agents, high fructose, and low pH directly impairs HDL functionality related to cholesterol efflux and particle maturation, whereas deglycosylation impairs HDL antioxidant capacity. On the other hand, the antioxidants lutein and zeaxanthin improve or preserve both HDL cholesterol efflux and antioxidant activity but have no effect on particle maturation.
Collapse
Affiliation(s)
- Jingyuan Zheng
- Department of Nutrition, University of California Davis, Davis, CA 95616, USA; (J.Z.); (B.V.H.); (J.K.A.); (X.T.); (N.R.K.)
| | - Brian V. Hong
- Department of Nutrition, University of California Davis, Davis, CA 95616, USA; (J.Z.); (B.V.H.); (J.K.A.); (X.T.); (N.R.K.)
| | - Joanne K. Agus
- Department of Nutrition, University of California Davis, Davis, CA 95616, USA; (J.Z.); (B.V.H.); (J.K.A.); (X.T.); (N.R.K.)
| | - Xinyu Tang
- Department of Nutrition, University of California Davis, Davis, CA 95616, USA; (J.Z.); (B.V.H.); (J.K.A.); (X.T.); (N.R.K.)
| | - Nola R. Klebaner
- Department of Nutrition, University of California Davis, Davis, CA 95616, USA; (J.Z.); (B.V.H.); (J.K.A.); (X.T.); (N.R.K.)
| | - Siyu Chen
- Department of Chemistry, University of California Davis, Davis, CA 95616, USA; (S.C.); (C.B.L.)
| | - Fei Guo
- Department of Molecular and Cellular Biology, University of California Davis, Davis, CA 95616, USA;
| | - Danielle J. Harvey
- Department of Public Health Sciences, University of California Davis, Davis, CA 95616, USA;
| | - Carlito B. Lebrilla
- Department of Chemistry, University of California Davis, Davis, CA 95616, USA; (S.C.); (C.B.L.)
| | - Angela M. Zivkovic
- Department of Nutrition, University of California Davis, Davis, CA 95616, USA; (J.Z.); (B.V.H.); (J.K.A.); (X.T.); (N.R.K.)
| |
Collapse
|
4
|
Naguib S, Torres ER, Lopez-Lee C, Fan L, Bhagwat M, Norman K, Lee SI, Zhu J, Ye P, Wong MY, Patel T, Mok SA, Luo W, Sinha S, Zhao M, Gong S, Gan L. APOE3-R136S mutation confers resilience against tau pathology via cGAS-STING-IFN inhibition. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.04.25.591140. [PMID: 38712164 PMCID: PMC11071490 DOI: 10.1101/2024.04.25.591140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2024]
Abstract
The Christchurch mutation (R136S) on the APOE3 (E3S/S) gene is associated with low tau pathology and slowdown of cognitive decline despite the causal PSEN1 mutation and high levels of amyloid beta pathology in the carrier1. However, the molecular effects enabling E3S/S mutation to confer protection remain unclear. Here, we replaced mouse Apoe with wild-type human E3 or E3S/S on a tauopathy background. The R136S mutation markedly mitigated tau load and protected against tau-induced synaptic loss, myelin loss, and spatial learning. Additionally, the R136S mutation reduced microglial interferon response to tau pathology both in vivo and in vitro, suppressing cGAS-STING activation. Treating tauopathy mice carrying wild-type E3 with cGAS inhibitor protected against tau-induced synaptic loss and induced similar transcriptomic alterations to those induced by the R136S mutation across brain cell types. Thus, cGAS-STING-IFN inhibition recapitulates the protective effects of R136S against tauopathy.
Collapse
Affiliation(s)
- Sarah Naguib
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
- Authors contributed equally
| | - Eileen Ruth Torres
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
- Authors contributed equally
| | - Chloe Lopez-Lee
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
- Neuroscience Graduate Program, Weill Cornell Medicine, New York, NY
- Authors contributed equally
| | - Li Fan
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Maitreyee Bhagwat
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Kendra Norman
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Se-In Lee
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Jingjie Zhu
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Pearly Ye
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Man Ying Wong
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Tark Patel
- Department of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada
| | - Sue-Ann Mok
- Department of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada
| | - Wenjie Luo
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Subhash Sinha
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Mingrui Zhao
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Shiaoching Gong
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
| | - Li Gan
- Helen and Robert Appel Institute for Alzheimer’s Disease Research, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY
- Neuroscience Graduate Program, Weill Cornell Medicine, New York, NY
| |
Collapse
|
8
|
Moser ED, Manemann SM, Larson NB, St Sauver JL, Takahashi PY, Mielke MM, Rocca WA, Olson JE, Roger VL, Remaley AT, Decker PA, Killian JM, Bielinski SJ. Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease-Related Dementias. Neurology 2023; 101:e1127-e1136. [PMID: 37407257 PMCID: PMC10513892 DOI: 10.1212/wnl.0000000000207595] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 05/12/2023] [Indexed: 07/07/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Prevention strategies for Alzheimer disease and Alzheimer disease-related dementias (AD/ADRDs) are urgently needed. Lipid variability, or fluctuations in blood lipid levels at different points in time, has not been examined extensively and may contribute to the risk of AD/ADRD. Lipid panels are a part of routine screening in clinical practice and routinely available in electronic health records (EHR). Thus, in a large geographically defined population-based cohort, we investigated the variation of multiple lipid types and their association to the development of AD/ADRD. METHODS All residents living in Olmsted County, Minnesota on the index date January 1, 2006, aged 60 years or older without an AD/ADRD diagnosis were identified. Persons with ≥3 lipid measurements including total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), or high-density lipoprotein cholesterol (HDL-C) in the 5 years before index date were included. Lipid variation was defined as any change in individual's lipid levels over time regardless of direction and was measured using variability independent of the mean (VIM). Associations between lipid variation quintiles and incident AD/ADRD were assessed using Cox proportional hazards regression. Participants were followed through 2018 for incident AD/ADRD. RESULTS The final analysis included 11,571 participants (mean age 71 years; 54% female). Median follow-up was 12.9 years with 2,473 incident AD/ADRD cases. After adjustment for confounding variables including sex, race, baseline lipid measurements, education, BMI, and lipid-lowering treatment, participants in the highest quintile of total cholesterol variability had a 19% increased risk of incident AD/ADRD, and those in highest quintile of triglycerides, variability had a 23% increased risk. DISCUSSION In a large EHR derived cohort, those in the highest quintile of variability for total cholesterol and triglyceride levels had an increased risk of incident AD/ADRD. Further studies to identify the mechanisms behind this association are needed.
Collapse
Affiliation(s)
- Ethan D Moser
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Sheila M Manemann
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Nicholas B Larson
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Jennifer L St Sauver
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Paul Y Takahashi
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Michelle M Mielke
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Walter A Rocca
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Janet E Olson
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Véronique L Roger
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Alan T Remaley
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Paul A Decker
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Jill M Killian
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
| | - Suzette J Bielinski
- From the Department of Quantitative Health Sciences (E.D.M., S.M.M., N.B.L., J.L.S.S., M.M.M., W.A.R., J.E.O., V.L.R., P.A.D., J.M.K., S.J.B.); Division of Community Internal Medicine (P.Y.T.), Department of Medicine, Mayo Clinic; Department of Neurology (M.M.M., W.A.R.), Rochester, MN; Department of Epidemiology and Prevention (M.M.M.), Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic Women's Health Research Center (W.A.R.); Department of Cardiovascular Medicine (V.L.R.), Mayo Clinic, Rochester, MN; Epidemiology and Community Branch (V.L.R.), National Heart, Lung, and Blood Institute, National Institutes of Health; and Lipoprotein Metabolism Laboratory (A.T.R.), Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
| |
Collapse
|
9
|
Lu H, Wang B, Liu Y, Wang D, Fields L, Zhang H, Li M, Shi X, Zetterberg H, Li L. DiLeu Isobaric Labeling Coupled with Limited Proteolysis Mass Spectrometry for High-Throughput Profiling of Protein Structural Changes in Alzheimer's Disease. Anal Chem 2023; 95:9746-9753. [PMID: 37307028 PMCID: PMC10330787 DOI: 10.1021/acs.analchem.2c05731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
High-throughput quantitative analysis of protein conformational changes has a profound impact on our understanding of the pathological mechanisms of Alzheimer's disease (AD). To establish an effective workflow enabling quantitative analysis of changes in protein conformation within multiple samples simultaneously, here we report the combination of N,N-dimethyl leucine (DiLeu) isobaric tag labeling with limited proteolysis mass spectrometry (DiLeu-LiP-MS) for high-throughput structural protein quantitation in serum samples collected from AD patients and control donors. Twenty-three proteins were discovered to undergo structural changes, mapping to 35 unique conformotypic peptides with significant changes between the AD group and the control group. Seven out of 23 proteins, including CO3, CO9, C4BPA, APOA1, APOA4, C1R, and APOA, exhibited a potential correlation with AD. Moreover, we found that complement proteins (e.g., CO3, CO9, and C4BPA) related to AD exhibited elevated levels in the AD group compared to those in the control group. These results provide evidence that the established DiLeu-LiP-MS method can be used for high-throughput structural protein quantitation, which also showed great potential in achieving large-scale and in-depth quantitative analysis of protein conformational changes in other biological systems.
Collapse
Affiliation(s)
- Haiyan Lu
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Bin Wang
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Yuan Liu
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Danqing Wang
- Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Lauren Fields
- Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Hua Zhang
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Miyang Li
- Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Xudong Shi
- Division of Otolaryngology, Department of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA
| | - Henrik Zetterberg
- Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 43141, Gothenburg, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 43130, Sweden
- Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK
- UK Dementia Research Institute at UCL, London, WC1N 3BG, UK
- Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, 999077, China
| | - Lingjun Li
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA
- Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA
- Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA
| |
Collapse
|